Puma Biotechnology (PBYI) Q4 2025 earnings review
Q4 Revenue Spike Masks a Severe 2026 Earnings Contraction
Puma finished FY25 with optical strength, as Q4 revenue surged 28% YoY to $75.5M, driven primarily by a massive $15.6M lumpy royalty payment. However, management's celebration of a 'third consecutive year of profitability' obscures a bleak forward outlook. FY26 guidance projects a ~60% collapse in Net Income to $10-$13M and a return to unprofitability in Q1 2026. Surging Gross-to-Net (GTN) adjustments—nearing 30%—and rising R&D costs for Alisertib are crushing margins, overshadowing the company's otherwise successful and disciplined debt paydown.
🐂 Bull Case
Puma has aggressively deleveraged, paying down its debt from $67.0M at the end of 2024 to just $22.5M by the end of 2025. This significantly reduces interest expenses and will free up meaningful cash flow by mid-2026.
The company is executing on its clinical pivot. Interim data readouts for both ALISCA-Breast1 and ALISCA-Lung1 are slated for Q2 2026, providing crucial, near-term catalysts that could validate the R&D spend.
🐻 Bear Case
Despite FY25's $31.1M net income, FY26 guidance of $10-$13M points to a severe deceleration. The expected Q1 2026 net loss of $8-$10M breaks a multi-year streak of quarterly profitability.
Driven by Inflation Reduction Act (IRA) Medicare Part D changes, GTN adjustments are accelerating rapidly, guided to hit 30% in Q1 2026. This permanently impairs the revenue capture of NERLYNX.
⚖️ Verdict: 🔴
Bearish. The core commercial asset (NERLYNX) is facing structural margin compression via GTN adjustments, and the reliance on lumpy international royalties to meet revenue figures is unsustainable. Until Alisertib proves its clinical worth, the stock faces a 'gap year' of declining earnings.
Key Themes
Severe Gross-to-Net (GTN) Margin Squeeze
A major operational red flag is the accelerating Gross-to-Net deduction. After hovering around 20.8% in early 2025, GTN jumped to roughly 26% in Q3 and is now guided to an alarming 29.5%-30.5% for Q1 2026, and 27.5%-28.5% for the full year. This is a structural headwind—likely driven by higher Medicare rebates from the IRA—that strips pure profit directly from the top line and is the primary culprit behind the weak 2026 earnings guidance.
Alisertib Clinical Progress
Management's entire future growth narrative hinges on Alisertib. R&D expenses accelerated to $62.1M in FY25 (up from $54.9M) to fund this. The company has locked in specific timelines for critical readouts: ALISCA-Breast1 and ALISCA-Lung1 will both deliver interim data in Q2 2026, with an updated readout for Breast1 in Q4 2026. This transforms 2026 into a 'show me' year for the pipeline.
Royalty Lumpiness Distorts Core Growth
Q4 2025 total revenue looked fantastic on the surface ($75.5M), but it was heavily propped up by $15.6M in royalty revenue (up from $4.7M YoY). However, total royalty guidance for all of FY26 is just $20-$23M. This indicates the Q4 print was a massive one-off anomaly—likely related to unpredictable partner shipments in China—and covers up the fact that core domestic product sales are stable-to-decelerating.
Disciplined SG&A Cost Control
While R&D costs are rising, management has exerted strong control over corporate overhead. Full-year SG&A dropped 12% YoY to $70.8M in FY25, partially due to the roll-off of AstraZeneca litigation fees. This discipline is the only lever management has left to defend the remaining $10-$13M of guided net income for 2026.
Other KPIs
Accelerating from $38.9 million in FY24. Strong cash conversion was the unsung hero of 2025, allowing Puma to self-fund its R&D expansion while simultaneously paying down nearly $45 million in debt. The company ended the year with $97.5M in cash and marketable securities.
Accelerating compared to $13.4 million in Q4 2024. While the bottom-line Net Income looked worse YoY due to non-cash deferred tax shifts (valuation allowance changes), core operational profitability was actually stronger in Q4, driven entirely by the high-margin royalty spike.
Guidance
Decelerating sharply. The midpoint of $11.5M implies a brutal 63% collapse from FY25's $31.1M. This shatters the narrative of sustained, expanding profitability, highlighting the toll of GTN margin compression and clinical trial costs.
Reversing. After posting a $13.4M profit in Q4, Q1 is guided to plunge deep into the red. This massive sequential swing is driven by the burn-off of Q4's lumpy royalty revenue and a massive spike in Q1 GTN adjustments.
Decelerating. The midpoint of $196M represents a 4% decline from FY25's $204.1M. This confirms that NERLYNX has passed its peak and is slowly eroding under competitive and pricing pressures.
Decelerating. Down from $24.3M in FY25. Given that $15.6M of FY25's royalties hit in Q4 alone, this guidance signals a return to a very anemic run-rate for international partner sales in the upcoming year.
Key Questions
Gross-to-Net Normalization
With Q1 2026 GTN guided to ~30%, how much of this is a structural, permanent increase driven by IRA Medicare Part D changes, and how much is standard Q1 seasonality? Where do you expect the long-term GTN floor to settle?
Contingency for Alisertib Readouts
If the Q2 2026 interim data for either ALISCA-Breast1 or ALISCA-Lung1 fails to meet your internal efficacy benchmarks, will you immediately halt those trials to defend your profitability, or is there a willingness to tolerate deeper net losses to push through to final readouts?
Royalty Volatility and China Exposure
Q4 saw a massive $15.6M in royalty revenue, yet full-year 2026 guidance is only $20-$23M. Can you break down the specific drivers of the Q4 spike and explain why partner demand (particularly in China) remains so unpredictable?